Plasma Hsp90 levels in patients with systemic sclerosis and relation to lung and skin involvement: a cross-sectional and longitudinal study.
Plasma Hsp90 levels in patients with systemic sclerosis and relation to lung and skin involvement: a cross-sectional and longitudinal study.
复制标题
DOI：
10.1038/s41598-020-79139-8
复制
发表时间：
2021-01-07
影响因子：
4.6
通讯作者：
Tomčík M
中科院分区：
文献类型：
--
作者：
Štorkánová H;Oreská S;Špiritović M;Heřmánková B;Bubová K;Komarc M;Pavelka K;Vencovský J;Distler JHW;Šenolt L;Bečvář R;Tomčík M
我们以前的研究表明，热休克蛋白（Hsp）90在系统性硬化症（SSc）患者皮肤中的表达增加。我们的目的是评估血浆热休克蛋白90在SSc和表征其与SSc相关的功能。招募92名SSc患者和92名年龄/性别匹配的健康对照进行横断面分析。纵向分析包括30名常规接受环磷酰胺治疗的SSc相关间质性肺病（ILD）患者。与健康对照组相比，SSc中的Hsp 90增加。热休克蛋白90与C反应蛋白呈正相关，与肺功能指标用力肺活量和一氧化碳弥散量呈负相关。在弥漫性皮肤（dc）SSc患者中，Hsp 90与改良Rodnan皮肤评分呈正相关。在接受环磷酰胺治疗的SSc-ILD患者中，基线与治疗1、6或12个月后的Hsp 90无差异。然而，基线Hsp 90可预测DLCO的12个月变化。这项研究表明，与年龄/性别匹配的健康对照相比，SSc患者的Hsp 90血浆水平升高。SSc中Hsp 90升高与炎症活动增加、肺功能恶化相关，而dcSSc中Hsp 90升高与皮肤受累程度相关。基线血浆Hsp 90可预测接受环磷酰胺治疗的SSc-ILD患者的DLCO的12个月变化。
Our previous study demonstrated increased expression of Heat shock protein (Hsp) 90 in the skin of patients with systemic sclerosis (SSc). We aimed to evaluate plasma Hsp90 in SSc and characterize its association with SSc-related features. Ninety-two SSc patients and 92 age-/sex-matched healthy controls were recruited for the cross-sectional analysis. The longitudinal analysis comprised 30 patients with SSc associated interstitial lung disease (ILD) routinely treated with cyclophosphamide. Hsp90 was increased in SSc compared to healthy controls. Hsp90 correlated positively with C-reactive protein and negatively with pulmonary function tests: forced vital capacity and diffusing capacity for carbon monoxide (DLCO). In patients with diffuse cutaneous (dc) SSc, Hsp90 positively correlated with the modified Rodnan skin score. In SSc-ILD patients treated with cyclophosphamide, no differences in Hsp90 were found between baseline and after 1, 6, or 12 months of therapy. However, baseline Hsp90 predicts the 12-month change in DLCO. This study shows that Hsp90 plasma levels are increased in SSc patients compared to age-/sex-matched healthy controls. Elevated Hsp90 in SSc is associated with increased inflammatory activity, worse lung functions, and in dcSSc, with the extent of skin involvement. Baseline plasma Hsp90 predicts the 12-month change in DLCO in SSc-ILD patients treated with cyclophosphamide.
登录
查看更多内容
影响因子：
3.4
作者：
Guo J;Chang C;Li W
通讯作者：
Li W
影响因子：
4.8
作者：
O'Reilly, Steven;Ciechomska, Marzena;van Laar, Jacob M.
通讯作者：
van Laar, Jacob M.
DOI：
10.1164/ajrccm.152.3.7663792
发表时间：
1995-09-01
影响因子：
24.7
作者：
通讯作者：
--
影响因子：
5.8
作者：
通讯作者：
--
影响因子：
2.8
作者：
Bohonowych, J. E.;Hance, M. W.;Nolan, K. D.;Defee, M.;Parsons, C. H.;Isaacs, J. S.
通讯作者：
Isaacs, J. S.